Trends in anxiolytic-hypnotic use and polypharmacy in Taiwan, 2002-2009: A nationwide, population-based survey

Psychiatric Services

Volumn 65, Issue 2, 2014, Pages 208-214

  Wang, Liang Jen ^a   Chen, Yi Chih ^b   Chen, Chih Ken ^b   Chou, Wen Jiun ^a   Chou, Miao Chun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE; BROMAZEPAM; BROTIZOLAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; CLOXAZOLAM; DIAZEPAM; ESTAZOLAM; FLUDIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC AGENT; LORAZEPAM; LORMETAZEPAM; MEDAZEPAM; MIDAZOLAM; NIMETAZEPAM; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; OXAZOLAM; PRAZEPAM; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOPICLONE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; HYPNOTIC SEDATIVE AGENT; PRESCRIPTION DRUG; PYRIDINE DERIVATIVE;

ARTICLE; DRUG FORMULATION; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PREVALENCE; TAIWAN; TIME SERIES ANALYSIS; TREND STUDY; EPIDEMIOLOGY; PUBLIC HEALTH; REGISTER; STATISTICS AND NUMERICAL DATA; TIME;

ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CHLORDIAZEPOXIDE; CLONAZEPAM; ESTAZOLAM; GABA MODULATORS; HUMANS; HYPNOTICS AND SEDATIVES; NATIONAL HEALTH PROGRAMS; POLYPHARMACY; PRESCRIPTION DRUGS; PYRIDINES; REGISTRIES; TAIWAN; TIME FACTORS;

EID: 84893674562     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300066     Document Type: Article

References (35)

1. Ohayon MM, Lader MH: Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. Journal of Clinical Psychiatry 63: 817-825, 2002
2. Paulose-Ram R, Safran MA, Jonas BS, et al: Trends in psychotropic medication use among US adults. Pharmacoepidemiology and Drug Safety 16:560-570, 2007
3. Chien IC, Bih SH, Chou YJ, et al: Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004. Psychiatric Services 58: 554-557, 2007
4. O'Brien CP: Benzodiazepine use, abuse, and dependence. Journal of Clinical Psychiatry 66(suppl 2):28-33, 2005
5. Barker MJ, Greenwood KM, Jackson M, et al: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18:37-48, 2004
6. Wu CS, Wang SC, Chang IS, et al: The association between dementia and longterm use of benzodiazepine in the elderly: nested case-control study using claims data. American Journal of Geriatric Psychiatry 17:614-620, 2009
7. Kripke DF, Langer RD, Kline LE: Hypnotics' association with mortality or cancer: a matched cohort study. British Medical Journal Open 2:e000850, 2012
8. Charlson F, Degenhardt L, McLaren J, et al: A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety 18:93-103, 2009
9. Belleville G: Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey. Canadian Journal of Psychiatry 55:558-567, 2010
10. Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865-889, 2000
11. Liappas IA, Malitas PN, Dimopoulos NP, et al: Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. Journal of Psychopharmacology 17:131-135, 2003
12. Victorri-Vigneau C, Dailly E, Veyrac G, et al: Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. British Journal of Clinical Pharmacology 64:198-209, 2007
13. Wang LJ, Ree SC, Chu CL, et al: Zolpidem dependence and withdrawal seizure- report of two cases. Psychiatria Danubina 23:76-78, 2011
14. Kassam A, Patten SB: Hypnotic use in a population-based sample of over thirtyfive thousand interviewed Canadians. Population Health Metrics 4:15, 2006
15. Assanangkornchai S, Sam-Angsri N, Rerngpongpan S, et al: Anxiolytic and hypnotic drug misuse in Thailand: findings from a national household survey. Drug and Alcohol Review 29:101-111, 2010
16. Fang SY, Chen CY, Chang IS, et al: Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug and Alcohol Dependence 104:140-146, 2009
17. Jaffe JH, Bloor R, Crome I, et al: A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 99: 165-173, 2004
18. Griffiths RR, Johnson MW: Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. Journal of Clinical Psychiatry 66(suppl 9):31-41, 2005
19. Wu CS, Lin YJ, Liu SK: Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey. Psychiatric Services 62:908-914, 2011
20. Shinfuku M, Uchida H, Tsutsumi C, et al: How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective. Pharmacopsychiatry 45:133-137, 2012
21. Gyllenberg D, Sourander A: Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study. Nordic Journal of Psychiatry 66: 336-342, 2012
22. Ineke Neutel C, Skurtveit S, Berg C: Polypharmacy of potentially addictive medication in the older persons-quantifying usage. Pharmacoepidemiology and Drug Safety 21:199-206, 2012
23. Mojtabai R, Olfson M: National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 67:26-36, 2010
24. Hausken AM, Skurtveit S, Tverdal A: Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiology and Drug Safety 16:913-918, 2007
25. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway, World Health Organization Collaborating Centre for Drug Statistics Methodology, 2009
26. Fu TS, Lee CS, Gunnell D, et al: Changing trends in the prevalence of common mental disorders in Taiwan: a 20-year repeated crosssectional survey. Lancet 381:235-241, 2013
27. Mellinger GD, Balter MB, Uhlenhuth EH: Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 251:375-379, 1984
28. Longo LP, Johnson B: Addiction: part I. benzodiazepines-side effects, abuse risk and alternatives. American Family Physician 61:2121-2128, 2000
29. Cates ME, Bishop MH, Davis LL, et al: Clonazepam for treatment of sleep disturbances associated with combatrelated posttraumatic stress disorder. Annals of Pharmacotherapy 38:1395-1399, 2004
30. Trenkwalder C, Hening WA, Montagna P, et al: Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Movement Disorders 23:2267-2302, 2008
31. Lader M: History of benzodiazepine dependence. Journal of Substance Abuse Treatment 8:53-59, 1991
32. Viktil KK, Blix HS, Moger TA, et al: Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. British Journal of Clinical Pharmacology 63: 187-195, 2007
33. Tomasi R, de Girolamo G, Santone G, et al: The prescription of psychotropic drugs in psychiatric residential facilities: a national survey in Italy. Acta Psychiatrica Scandinavica 113:212-223, 2006
34. Pradel V, Delga C, Rouby F, et al: Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator. CNS Drugs 24:611-620, 2010
35. Uhlenhuth EH, DeWit H, Balter MB, et al: Risks and benefits of long-term benzodiazepine use. Journal of Clinical Psychopharmacology 8:161-167, 1988